Industry News

Regeneron, Avalanche Biotechnologies to collaborate on gene therapy products

Regeneron Pharmaceuticals and Avalanche Biotechnologies announced a collaboration agreement centered on the development of novel ophthalmic genetic therapy products, according to a press release.

Avalanche’s AVA-101 is currently undergoing a phase 2a trial for wet age-related macular degeneration. Avalanche also has a proprietary adeno-associated virus-based gene therapy discovery and development technology called the Ocular BioFactory platform, according to the release.

The Ocular BioFactory platform technology is optimized for ophthalmology and utilizes a directed evolution approach to generate novel drug candidates.

Regeneron will make an upfront cash payment and contingent payments up to $640 million.

Regeneron gains exclusive global rights for each product in eight therapeutic target areas under development and has a right of first negotiation for certain properties of AVA-101, the release said.

Regeneron Pharmaceuticals and Avalanche Biotechnologies announced a collaboration agreement centered on the development of novel ophthalmic genetic therapy products, according to a press release.

Avalanche’s AVA-101 is currently undergoing a phase 2a trial for wet age-related macular degeneration. Avalanche also has a proprietary adeno-associated virus-based gene therapy discovery and development technology called the Ocular BioFactory platform, according to the release.

The Ocular BioFactory platform technology is optimized for ophthalmology and utilizes a directed evolution approach to generate novel drug candidates.

Regeneron will make an upfront cash payment and contingent payments up to $640 million.

Regeneron gains exclusive global rights for each product in eight therapeutic target areas under development and has a right of first negotiation for certain properties of AVA-101, the release said.